
    
      A prospective, multicenter trial designed to confirm that the safety and effectiveness of the
      Lotus Valve System in the Japanese medical environment are consistent with the REPRISE III
      results for TAVR in symptomatic subjects who have calcific, severe native aortic stenosis and
      who are at extreme or high risk for surgical valve replacement.
    
  